Wound-Associated Skin Fibrosis: Mechanisms and Treatments Based on Modulating the Inflammatory Response

Tanya      J. Shaw; Kazuo      Kishi; Ryoichi      Mori

doi:10.2174/1871530311006040320

Abstract

Skin fibrosis, in its mildest form, may present only a minor aesthetic problem, but in the most severe cases it can lead to debilitating pathologies of the skin, for example keloid and hypertrophic scars, and systemic sclerosis. In recent years, extensive basic research aimed at understanding the molecular mechanisms underlying fibrosis has revealed an impressive but baffling number of genes, molecules, and cell types that may contribute to this problem. However, one recurring and consistent theme in these studies is that inflammatory cells and their secreted mediators appear to be leading culprits in activating dermal fibroblasts to become fibrotic. This review will first describe the histology of normal versus fibrotic skin, and will also describe the process of wound repair, a primary cause of skin fibrosis. We will then focus on what is currently known about the molecular mechanisms underlying skin fibrosis, with particular attention paid to how inflammation contributes. Finally, current treatment strategies and emerging therapeutic targets will be discussed.

Keywords: Skin, scar, fibrosis, inflammation, cytokine, antisense oligodeoxynucleotide, collagen, wound, collagen type I, fibronectin, matrix-degrading metalloproteinases, keloid scars, telangiectasia, spider veins, D-penicillamine, colchicine, azathioprine, cyclosporine, Surgical resection, radiation therapy, and photo therapies, epidermal growth factor, Arachidonic acid, cyclooxygenase, lipoxygenase, prostaglandins, thromboxane, leukotrienes, Intracellular adhesion molecule-1, activator protein 1, Fos-related antigen-2, early growth response gene-1, peroxisome proliferator-activated receptor gamma, urokinase-type plasminogen activator receptor